TigerResearch/tigerbot-earning-plugin huggingface dataset:
2.期初账面价值|116,063,222.44|||116,063,222.44
项目|账面价值|未办妥产权证书原因
龙华路六层楼|2,191,057.09|抵债取得,尚未办理权证
合计|2,191,057.09|
项目|期末余额|期初余额
固定资产|1,601,156,573.01|1,796,625,980.83
固定资产清理|0.00|0.00
合计|1,601,156,573.01|1,796,625,980.83
项目|房屋及建筑物|机器设备|运输工具|其他/办公设备|合计
一、账面原值:|||||
1.期初余额|1,670,856,432.92|1,087,588,506.16|16,691,641.39|49,947,081.65|2,825,083,662.12
2.本期增加金额|15,160,407.00|10,859,404.91|391,189.80|9,314,891.21|35,725,892.92
(1)购|1,668,262.44|7,221,582.37|391,189.80|853,788.44|10,134,823.05
置|||||
(2)在建工程转入|13,454,350.29|3,637,822.54|0.00|8,461,102.77|25,553,275.60
(3)企业合并增加|||||
(4)其他增加|37,794.27|0.00|0.00|0.00|37,794.27
3.本期减少金额|120,441,925.41|60,095,771.64|1,699,070.32|7,727,234.24|189,964,001.61
(1)处置或报废|41,366,453.92|35,507,187.84|441,908.54|458,419.12|77,773,969.42
(2)处置子公司及其他减少|79,075,471.49|24,588,583.80|1,257,161.78|7,268,815.12|112,190,032.19
4.期末余额|1,565,574,914.51|1,038,352,139.43|15,383,760.87|51,534,738.62|2,670,845,553.43
二、累计折旧|||||
1.期初余额|417,771,220.49|500,276,381.09|9,216,928.35|28,359,454.85|955,623,984.78
2.本期增加金额|49,556,824.16|73,110,206.31|1,252,403.27|4,062,488.36|127,981,922.10
(1)计提|49,556,824.16|73,110,206.31|1,252,403.27|4,062,488.36|127,981,922.10
|||||
3.本期减少金额|31,742,192.58|33,413,810.10|1,315,443.29|5,211,447.26|71,682,893.23
(1)处置或报废|16,618,398.76|18,093,372.05|268,059.91|431,833.99|35,411,664.71
(2)处置子公司及其他减少|15,123,793.82|15,320,438.05|1,047,383.38|4,779,613.27|36,271,228.52
4.期末余额|435,585,852.07|539,972,777.30|9,153,888.33|27,210,495.95|1,011,923,013.65
三、减值准备|||||
1.期初余额|44,548,717.89|28,284,978.62|0.00|0.00|72,833,696.51
2.本期增加金额|||||
(1)计提|||||
|||||
3.本期减少金额|8,751,720.79|6,316,008.95|0.00|0.00|15,067,729.74
(1)处置或报废|8,751,720.79|6,316,008.95|0.00|0.00|15,067,729.74
|||||
4.期末余额|35,796,997.10|21,968,969.67|0.00|0.00|57,765,966.77
四、账面价值|||||
1.期末账面价值|1,094,192,065.34|476,410,392.46|6,229,872.54|24,324,242.67|1,601,156,573.01
2.期初账面价值|1,208,536,494.54|559,027,146.45|7,474,713.04|21,587,626.80|1,796,625,980.83
项目|账面原值|累计折旧|减值准备|账面价值|备注
房屋及建筑物|84,895,132.22|19,657,797.34|35,796,997.10|29,440,337.78|
机器设备|75,037,852.38|54,371,949.48|20,665,902.90|0.00|
合计|159,932,984.60|74,029,746.82|56,462,900.00|29,440,337.78|
项目|期末账面价值
房屋及建筑物|178,305,785.33
机器设备|48,734,843.72
运输设备|34,878.98
其他设备|4,076,444.21
合计|231,151,952.24
项目|账面价值|未办妥产权证书的原因
房屋及建筑物|47,600,458.75|正在办理中
合计|47,600,458.75|
项目|期末余额|期初余额
在建工程|1,103,920,624.62|904,984,611.38
工程物资|0.00|0.00
合计|1,103,920,624.62|904,984,611.38
项目|期末余额|||期初余额||
|账面余额|减值准备|账面价值|账面余额|减值准备|账面价值
重庆天地医药产业园项目第一期|875,904,893.41||875,904,893.41|660,093,453.11||660,093,453.11
海南海药生物|100,008,198.||100,008,198.|100,008,198.||100,008,198.
医药产业园 FDA 认证建设项目|13||13|13||13
江苏普健厂区建设工程|92,430,047.69||92,430,047.69|100,521,880.42||100,521,880.42
江苏普健净化工程|13,718,644.30||13,718,644.30|18,219,999.96||18,219,999.96
江苏普健设备工程|11,310,947.21||11,310,947.21|11,310,947.21||11,310,947.21
汉阔全流程、二级平台、五位一体建设|4,058,115.46||4,058,115.46|3,042,468.20||3,042,468.20
盐城开元自动化改造|1,439,164.16||1,439,164.16|7,215,117.76||7,215,117.76
小项目加总|5,050,614.26||5,050,614.26|4,572,546.59||4,572,546.59
合计|1,103,920,624.62||1,103,920,624.62|904,984,611.38||904,984,611.38
项目名称|预算数|期初余额|本期增加金额|本期转入固定资产金额|本期其他减少金额|期末余额|工程累计投入占预算比例|工程进度|利息资本化累计金额|其中:本期利息资本化金额|本期利息资本化率|资金来源
重庆天地医药产业园项目第一期|1,175,000,000.00|660,093,453.11|215,811,440.30|0.00|0.00|875,904,893.41|74.55%|97.00%|3,757,322.22|1,491,222.22|1.41%|募股资金
海南海药生物医药产业园FDA认证建设项目|720,768,400.00|100,008,198.13|5,572,966.97|5,572,966.97|0.00|100,008,198.13|94.63%|99.00%|0.00|0.00|0.00%|募股资金
江苏普健厂区建设工程|120,000,000.00|100,521,880.42|0.00|0.00|8,091,832.73|92,430,047.69|57.21%|80.00%|0.00|0.00|0.00%|其他
江苏普健净化工程|19,860,000.00|18,219,999.96|0.00|0.00|4,501,355.66|13,718,644.30|60.00%|91.74%|0.00|0.00|0.00%|其他
江苏普健|35,000,000|11,310,947|0.00|0.00|0.00|11,310,947|29.06%|32.32%|0.00|0.00|0.00%|其他
设备工程|.00|.21||||.21||||||
合计|2,070,628,400.00|890,154,478.83|221,384,407.27|5,572,966.97|12,593,188.39|1,093,372,730.74|||3,757,322.22|1,491,222.22|1.41%|
项目|房屋及建筑物|合计
一、账面原值||
1.期初余额|1,971,510.22|1,971,510.22
2.本期增加金额||
||
3.本期减少金额|54,257.84|54,257.84
其他减少|54,257.84|54,257.84
4.期末余额|1,917,252.38|1,917,252.38
二、累计折旧||
1.期初余额||
2.本期增加金额|474,489.81|474,489.81
(1)计提|474,489.81|474,489.81
||
3.本期减少金额||
(1)处置||
||
4.期末余额|474,489.81|474,489.81
三、减值准备||
1.期初余额||
2.本期增加金额||
(1)计提||
||
3.本期减少金额||
(1)处置||
||
4.期末余额||
四、账面价值||
1.期末账面价值|1,442,762.57|1,442,762.57
2.期初账面价值|1,971,510.22|1,971,510.22
项目|土地使用权|专利权|非专利技术|软件|换地权益证|合计
一、账面原值||||||
1.期初余额|366,588,685.19|21,948,104.20|251,572,702.54|3,374,915.58|4,528,479.72|648,012,887.23
2.本期增加金额|0.00|4,500,000.00|27,176,381.40|506,787.11|0.00|32,183,168.51
(1)购置|0.00|4,500,000.00|0.00|506,787.11|0.00|5,006,787.11
(2)内部研发|0.00|0.00|27,176,381.40|0.00|0.00|27,176,381.40
(3)企业合并增加||||||
||||||
3.本期减少金额|35,087,773.12|1,000,000.00|124,104,246.66|0.00|0.00|160,192,019.78
(1)处置|18,832,963.12|0.00|0.00|0.00|0.00|18,832,963.12
(2)处置子公司|16,254,810.00|1,000,000.00|124,104,246.66|0.00|0.00|141,359,056.66
4.期末余额|331,500,912.07|25,448,104.20|154,644,837.28|3,881,702.69|4,528,479.72|520,004,035.96
二、累计摊销||||||
1.期初余额|89,421,353.65|15,757,679.77|83,471,151.29|1,282,569.62|0.00|189,932,754.33
2.本期增加金额|8,421,441.71|603,315.92|12,005,466.98|350,118.55|0.00|21,380,343.16
(1)计提|8,421,441.71|603,315.92|12,005,466.98|350,118.55|0.00|21,380,343.16
||||||
3.本期减少金额|5,362,348.78|999,984.27|29,935,749.63|0.00|0.00|36,298,082.68
(1)处置|2,057,204.08|0.00|0.00|0.00|0.00|2,057,204.08
(2)处置子公司|3,305,144.70|999,984.27|29,935,749.63|0.00|0.00|34,240,878.60
4.期末余额|92,480,446.58|15,361,011.42|65,540,868.64|1,632,688.17|0.00|175,015,014.81
三、减值准备||||||
1.期初余额|0.00|0.00|0.00|0.00|286,479.72|286,479.72
2.本期增加金额||||||
(1)计提||||||
||||||
3.本期减少金额||||||
(1)处置||||||
||||||
4.期末余额|0.00|0.00|0.00|0.00|286,479.72|286,479.72
四、账面价值||||||
1.期末账面价值|239,020,465.49|10,087,092.78|89,103,968.64|2,249,014.52|4,242,000.00|344,702,541.43
2.期初账面价值|277,167,331.54|6,190,424.43|168,101,551.25|2,092,345.96|4,242,000.00|457,793,653.18
本期末通过公司内部研发形成的无形资产占无形资产余额的比例5.29%。
项目|期初余额|本期增加金额|||本期减少金额|||期末余额
||内部开发支出|其他||确认为无形资产|转入当期损益|其他|
仿制药等开发支出|286,030,309.59|96,863,802.27|41,434,130.41||27,570,770.74|45,174,724.30|88,273,875.51|263,308,871.72
合计|286,030,309.59|96,863,802.27|41,434,130.41||27,570,770.74|45,174,724.30|88,273,875.51|263,308,871.72
被投资单位名称或形成商誉的事项|期初余额|本期增加||本期减少||期末余额
||企业合并形成的||处置||
鄂州鄂钢医院有限公司|240,172,379.17|||||240,172,379.17
盐城开元医药化工有限公司|30,700,184.32|||||30,700,184.32
湖南海药鸿星堂医药有限公司|5,268,740.03|||||5,268,740.03
湖南柳城中药饮片有限公司|1,799,088.20|||||1,799,088.20
合计|277,940,391.72|||||277,940,391.72
被投资单位名称或形成商誉的事项|期初余额|本期增加||本期减少||期末余额
||计提||处置||
鄂州鄂钢医院有限公司|52,628,700.00|||||52,628,700.00
湖南海药鸿星堂医药有限公司|5,268,740.03|||||5,268,740.03
湖南柳城中药饮片有限公司|1,799,088.20|||||1,799,088.20
合计|59,696,528.23|||||59,696,528.23
上述公司商誉减值测试的资产组的构成为形成商誉的资产组涉及的资产,组成资产组的资产包括固定资产、无形资产等。
包含商誉的资产组可收回金额按照预计未来现金流量的现值计算,其预计现金流量根据公司批准的5 年期现金流量预测为基础,现金流量预测使用合理的折现率,公司根据历史实际经营数据、行业发展趋势、预期收入增长率、毛利率等指标编制预测未来5 年现金流量,预测期以后的现金流量维持不变。
减值测试中采用的其他关键数据包括:产品预计售价、销量、营业成本及其他相关费用。公司根据历史经验及对市场发展的预测确定上述关键数据。公司采用合理的折现率作为计算未来现金流量现值的税前折现率,采用的折现率已考虑了公司的资本成本、市场预期报酬率等因素,反映了各资产组的特定风险。
根据管理层对可收回金额的预计情况,公司收购上述公司形成的商誉发生减值5,969.65 万元。
项目|期初余额|本期增加金额|本期摊销金额|其他减少金额|期末余额
装修费|31,216,627.88|5,391,938.89|6,763,764.14|535,779.81|29,309,022.82
服务费|550,313.65|0.00|550,313.65|0.00|0.00
医院信息工程|1,398,223.75|619,800.00|445,544.23|0.00|1,572,479.52
其他|136,000.24|0.00|33,999.96|102,000.28|0.00
合计|33,301,165.52|6,011,738.89|7,793,621.98|637,780.09|30,881,502.34
项目|期末余额||期初余额|
|可抵扣暂时性差异|递延所得税资产|可抵扣暂时性差异|递延所得税资产
资产减值准备|281,528,624.83|51,711,959.22|293,113,492.54|54,034,724.53
内部交易未实现利润|0.00|0.00|0.00|0.00
可抵扣亏损|480,288,697.36|72,043,304.60|611,336,968.69|104,529,509.98
递延收益|51,863,715.87|7,779,557.38|21,665,541.13|3,249,831.17
合计|813,681,038.06|131,534,821.20|926,116,002.36|161,814,065.68
项目|期末余额||期初余额|
|应纳税暂时性差异|递延所得税负债|应纳税暂时性差异|递延所得税负债
交易性金融资产公允价值变动|97,935,140.00|24,445,185.00|491,517,621.44|122,834,405.36
合计|97,935,140.00|24,445,185.00|491,517,621.44|122,834,405.36
项目|递延所得税资产和负债期末互抵金额|抵销后递延所得税资产或负债期末余额|递延所得税资产和负债期初互抵金额|抵销后递延所得税资产或负债期初余额
递延所得税资产||131,534,821.20||161,814,065.68
递延所得税负债||24,445,185.00||122,834,405.36
项目|期末余额|期初余额
可抵扣暂时性差异|914,029,089.39|731,457,989.88
可抵扣亏损|1,034,285,204.67|1,373,685,856.39
合计|1,948,314,294.06|2,105,143,846.27
年份|期末金额|期初金额|备注
2022|0.00|32,155,523.06|
2023|78,703,313.80|84,936,261.49|
2024|183,994,304.40|195,187,485.54|
2025|347,069,828.33|637,284,802.48|
2026|370,860,827.65|424,121,783.82|
2027|53,656,930.49|0.00|
合计|1,034,285,204.67|1,373,685,856.39|
项目|期末余额|||期初余额||
|账面余额|减值准备|账面价值|账面余额|减值准备|账面价值
长期资产购置款|22,723,652.93|0.00|22,723,652.93|27,642,730.80|0.00|27,642,730.80
预付无形资产款|2,430,951.19|0.00|2,430,951.19|13,122,893.03|0.00|13,122,893.03
合计|25,154,604.12|0.00|25,154,604.12|40,765,623.83|0.00|40,765,623.83
项目|期末余额|期初余额
质押借款|100,000,000.00|202,200,000.00
抵押借款|254,151,058.33|257,033,333.33
保证借款|1,439,344,997.01|1,034,832,300.00
信用借款|209,913,200.00|0.00
合计|2,003,409,255.34|1,494,065,633.33
本期末已逾期未偿还的短期借款总额为0.00 元
种类|期末余额|期初余额
商业承兑汇票|0.00|161,350,000.00
银行承兑汇票|80,409,097.02|281,933,329.52
合计|80,409,097.02|443,283,329.52
项目|期末余额|期初余额
应付材料款|105,483,190.08|140,974,270.94
应付货款|140,123,564.22|186,559,756.86
应付工程款|94,123,440.46|106,090,237.16
应付设备款|68,520,937.27|31,838,950.40
其他|35,026,251.59|23,515,191.50
合计|443,277,383.62|488,978,406.86
项目|期末余额|未偿还或结转的原因
江苏龙宇建设工程有限公司|23,402,483.34|未结算
广东海王医药集团有限公司|10,335,518.62|诉讼纠纷
江苏腾裕顺建设有限公司|4,599,620.98|未结算
海南第一建设工程有限公司|4,100,000.00|未结算
陕西重点经泰电子工程有限公司|2,599,165.39|未结算
宁波信远膜工业股份有限公司|2,552,000.00|未结算
杭州和利时自动化有限公司|2,538,294.83|未结算
苏州第四制药厂有限公司|2,534,294.27|未结算
北京佳定机电设备安装有限责任公司|2,355,727.11|未结算
合计|55,017,104.54|
项目|期末余额|期初余额
预收租金|412,019.82|30,000.00
合计|412,019.82|30,000.00
项目|期末余额|期初余额
预收货款|36,695,766.01|45,137,593.44
合计|36,695,766.01|45,137,593.44
项目|期初余额|本期增加|本期减少|期末余额
一、短期薪酬|31,095,877.96|224,739,262.91|233,179,882.16|22,655,258.71
二、离职后福利-设定提存计划|351,223.15|20,407,269.65|20,635,923.04|122,569.76
三、辞退福利|0.00|537,599.57|537,599.57|0.00
合计|31,447,101.11|245,684,132.13|254,353,404.77|22,777,828.47
项目|期初余额|本期增加|本期减少|期末余额
1、工资、奖金、津贴和补贴|29,828,385.81|179,347,124.65|190,963,298.45|18,212,212.01
2、职工福利费|234,670.00|13,728,264.84|13,493,617.81|469,317.03
3、社会保险费|222,403.65|11,976,574.37|12,125,861.29|73,116.73
其中:医疗保险费|218,836.34|10,810,312.36|10,956,320.36|72,828.34
工伤保险费|3,567.31|768,442.27|771,721.19|288.39
生育保险费|0.00|397,819.74|397,819.74|0.00
4、住房公积金|183,803.58|7,805,014.00|7,900,247.00|88,570.58
5、工会经费和职工教育经费|626,614.92|3,369,615.51|3,566,855.07|429,375.36
其他短期薪酬|0.00|8,512,669.54|5,130,002.54|3,382,667.00
合计|31,095,877.96|224,739,262.91|233,179,882.16|22,655,258.71
项目|期初余额|本期增加|本期减少|期末余额
1、基本养老保险|340,589.32|19,746,842.35|19,968,686.18|118,745.49
2、失业保险费|10,633.83|660,427.30|667,236.86|3,824.27
合计|351,223.15|20,407,269.65|20,635,923.04|122,569.76
项目|期末余额|期初余额
增值税|24,992,263.83|15,566,005.23
企业所得税|1,903,460.40|88,313.64
个人所得税|432,384.19|1,099,769.20
城市维护建设税|2,130,871.07|2,545,976.93
房产税|2,092,559.19|2,295,324.66
土地使用税|387,257.14|310,334.64
教育费附加|1,593,885.29|1,859,438.39
其他|113,958.05|171,392.78
合计|33,646,639.16|23,936,555.47
项目|期末余额|期初余额
应付利息|6,003,146.57|6,003,146.57
应付股利|3,975,170.80|3,975,170.80
其他应付款|633,334,211.79|1,036,494,641.82
合计|643,312,529.16|1,046,472,959.19
项目|期末余额|期初余额
非金融机构借款应付利息|6,003,146.57|6,003,146.57
合计|6,003,146.57|6,003,146.57
重要的已逾期未支付的利息情况:不适用
项目|期末余额|期初余额
工行海南信托投资公司|3,267,489.60|3,267,489.60
汇通国际信托投资公司|384,566.15|384,566.15
海南保险职工经济技术开发服务公司|127,091.70|127,091.70
其他|196,023.35|196,023.35
合计|3,975,170.80|3,975,170.80
项目|期末余额|期初余额
借款本息|541,851,190.54|849,348,305.52
往来款|16,839,052.47|52,900,936.64
押金及保证金|51,613,384.16|55,972,083.26
预提费用|4,947,698.49|56,668,774.93
应付出资款|0.00|782,707.50
其他|18,082,886.13|20,821,833.97
合计|633,334,211.79|1,036,494,641.82
项目|期末余额|未偿还或结转的原因
北京凯正生物工程发展有限责任公司|29,395,833.31|未结算
台州三隆进出口有限公司|11,550,960.80|未结算
方芳|10,000,000.00|未结算
滨海临海资产管理有限公司|10,000,000.00|未结算
鲁鹰|8,723,641.64|未结算
陈光华|5,649,188.81|保证金
邱卫中|5,500,000.00|未结算
合计|80,819,624.56|
项目|期末余额|期初余额
一年内到期的长期借款|572,428,588.89|732,075,069.19
一年内到期的长期应付款|162,277,088.97|367,057,189.02
一年内到期的租赁负债|547,970.12|345,640.14
合计|735,253,647.98|1,099,477,898.35
项目|期末余额|期初余额
待转销销项税|3,517,785.48|4,439,874.22
合计|3,517,785.48|4,439,874.22
项目|期末余额|期初余额
质押借款|0.00|271,000,000.00
抵押借款|525,156,597.22|259,980,000.00
保证借款|134,091,666.67|155,188,200.00
合计|659,248,263.89|686,168,200.00
项目|期末余额|期初余额
1 年以内|242,485.88|388,337.73
1-2 年|465,124.94|595,023.25
2-3 年|581,686.51|629,819.97
3-4 年|247,056.00|555,134.32
减:未确认融资费用|-177,261.76|-253,469.26
减:一年内到期的租赁负债|-547,970.12|-345,640.14
合计|811,121.45|1,569,205.87
项目|期末余额|期初余额
长期应付款|17,765,821.90|179,090,136.30
合计|17,765,821.90|179,090,136.30
项目|期末余额|期初余额
应付融资租赁款|180,042,910.87|546,147,325.32
减:一年内到期的长期应付款|162,277,088.97|367,057,189.02
合计|17,765,821.90|179,090,136.30
项目|期末余额|期初余额|形成原因
未决诉讼|157,817,263.91|153,831,706.41|
合计|157,817,263.91|153,831,706.41|
项目|期初余额|本期增加|本期减少|期末余额|形成原因
政府补助|59,947,591.90|31,330,000.00|22,516,779.09|68,760,812.81|详见下表
医疗设备捐赠|4,185,518.88|0.00|480,310.32|3,705,208.56|捐赠医疗设备
合计|64,133,110.78|31,330,000.00|22,997,089.41|72,466,021.37|--
负债项目|期初余额|本期新增补助金额|本期计入营业外收入金额|本期计入其他收益金额|本期冲减成本费用金额|其他变动|期末余额|与资产相关/与收益相关
乌杨项目国家支持先进制造业专项补贴||30,330,000.00|||||30,330,000.00|与资产相关
专项生产线|13,437,083.28||||||13,437,083.28|与资产相关
滨海医药产业园招商服务中心项目投资奖励资金|10,000,000.00||||||10,000,000.00|与资产相关
企业设备资助款|4,842,210.07|||605,679.96|||4,236,530.11|与资产相关
乌杨土地返还基础设施费用2020.10|1,929,200.01|||220,480.00|||1,708,720.01|与资产相关
乌杨土地|1,842,105|||157,894.7|||1,684,210|与资产相
返还基础设施费用2021.4|.26|||4|||.52|关
工业发展专项资金|1,737,500.00|||150,000.00|||1,587,500.00|与资产相关
乌杨土地返还基础设施费用2020.11|1,764,985.99|||201,680.67|||1,563,305.32|与资产相关
1 类创新药 YF-HY-2020-008|1,766,666.69|||399,999.96|||1,366,666.73|与资产相关
乌杨土地返还基础设施费用2022.12||1,000,000.00||63,269.85|||936,730.15|与资产相关
湖南省发改委2018年湘西地区重大产业项目奖补资金110万|971,666.66|||36,666.67|||934,999.99|与资产相关
第二条头孢类原料药审生产线新版GMP改造项目|565,500.00|||87,000.00|||478,500.00|与资产相关
海口市科学技术工业信息局设备资助奖励资金|414,570.00|||95,670.00|||318,900.00|与资产相关
政府补助-库区承接产业转移项目补助资金|113,333.26|||5,666.67|||107,666.59|与资产相关
海口市科学技术工业信息化局2014 年海口市中小企业发展专项资金|80,000.07|||39,999.96|||40,000.11|与资产相关
市级民营经济专项资金2013|70,000.00|||40,000.00|||30,000.00|与资产相关
人工耳蜗及助听设备调机维护实训中心建设项目|11,048,000.00|||2,358,786.37||-8,689,213.63||与资产相关
高质量发|1,848,888|||42,569.64||-||与资产相
展政策专项资金|.89|||||1,806,319.25||关
人工耳蜗建设项目|1,157,894.72|||21,052.68||-1,136,842.04||与资产相关
上海市国库收付中心零余额专户服务业引导2021020608 基于云服务的国产人工耳蜗远程调机服务系统平台建设|800,000.00|||15,789.48||-784,210.52||与资产相关
第二代国产人工耳蜗临床验证研究|767,999.84|||85,818.72||-682,181.12||与资产相关
市级国库拨付中心|750,000.00|||105,263.16||-644,736.84||与资产相关
国产人工耳蜗系统优化设计|552,631.92|||||-552,631.92||与资产相关
产业振兴和技术改造项目2013 年中央预算内投资项目|540,000.00|||540,000.00||||与资产相关
“抗肿瘤新药-苯达莫司汀原料及制剂的研制”的专项补助|500,000.00|||500,000.00||||与资产相关
上海市科学技术委员会LCI-21P3 型人工耳蜗植入体21S31905800|400,000.00|||176,607.60||-223,392.40||与资产相关
国产人工耳蜗系统优化设计|305,555.20|||16,842.12||-288,713.08||与资产相关
多通道国产耳蜗匹配资金|294,117.68|||56,000.04||-238,117.64||与资产相关
第二代国产人工耳|287,594.96|||||-287,594.9||与资产相关
蜗临床验证研究||||||6||
新一代人工耳蜗语音处理器的研制|279,999.80|||||-279,999.80||与资产相关
人工耳蜗语音处理器的改进|210,525.88|||||-210,525.88||与资产相关
植入式骶神经刺激系统的研制|168,420.92|||||-168,420.92||与资产相关
财政专项资金|160,833.33|||160,833.33||||与资产相关
国家中小企业发展专项-专利补贴|157,894.68|||||-157,894.68||与资产相关
多通道国产耳蜗匹配资金|131,579.08|||||-131,579.08||与资产相关
市级民营经济专项资金2012|45,000.00|||45,000.00||||与资产相关
普陀区区级科技创新项目资助资金|5,833.71|||||-5,833.71||与资产相关
合计|59,947,591.90|31,330,000.00||6,228,571.62||-16,288,207.47|68,760,812.81|
项目|期末余额|期初余额
中国农发重点建设基金有限公司|93,000,000.00|93,000,000.00
合计|93,000,000.00|93,000,000.00
|期初余额|本次变动增减(+、-)|||||期末余额
||发行新股|送股|公积金转股|其他|小计|
股份总数|1,297,365,126.00||||||1,297,365,126.00
项目|期初余额|本期增加|本期减少|期末余额
资本溢价(股本溢价)|2,639,168,826.16|||2,639,168,826.16
其他资本公积|169,233,952.83|||169,233,952.83
合计|2,808,402,778.99|||2,808,402,778.99
项目|期初余额|本期发生额||||||期末余额
||本期所得税前发生额|减:前期计入其他综合收益当期转入损益|减:前期计入其他综合收益当期转入留存收益|减:所得税费用|税后归属于母公司|税后归属于少数股东|
一、不能重分类进损益的其他综合收益|-40,043,680.48|-256,760.00|||-57,790.00|-198,970.00||-40,242,650.48
其他权益工具投资公允价值变动|-40,043,680.48|-256,760.00|||-57,790.00|-198,970.00||-40,242,650.48
二、将重分类进损益的其他综合收益|871,413.11|5,247,397.75||||5,247,397.75||6,118,810.86
其中:权益法下可转损益的其他综合收益|4,417,954.80|||||||4,417,954.80
外币财务报表折算差额|-3,546,541.69|5,247,397.75||||5,247,397.75||1,700,856.06
其他综合收益合计|-39,172,267.37|4,990,637.75|||-57,790.00|5,048,427.75||-34,123,839.62
项目|期初余额|本期增加|本期减少|期末余额
法定盈余公积|90,919,423.22|||90,919,423.22
合计|90,919,423.22|||90,919,423.22
项目|本期|上期
调整前上期末未分配利润|-2,008,287,774.02|-441,997,816.72
调整后期初未分配利润|-2,008,287,774.02|-441,997,816.72
加:本期归属于母公司所有者的净利润|10,515,675.29|-1,555,415,451.91
其他|0.00|-10,874,505.39
期末未分配利润|-1,997,772,098.73|-2,008,287,774.02
项目|本期发生额||上期发生额|
|收入|成本|收入|成本
主营业务|1,757,230,310.63|1,003,146,671.52|2,042,428,794.40|1,220,170,039.57
其他业务|21,821,882.55|7,677,104.68|16,633,967.45|7,874,297.55
合计|1,779,052,193.18|1,010,823,776.20|2,059,062,761.85|1,228,044,337.12
项目|本年度|具体扣除情况|上年度|具体扣除情况
营业收入金额|1,779,052,193.18|无|2,059,062,761.85|无
营业收入扣除项目合计金额|21,821,882.55|主要为销售材料、资产出租,不属于主营范围,需扣除|16,633,967.45|主要为销售材料、资产出租,不属于主营范围,需扣除
营业收入扣除项目合计金额占营业收入的比重|1.23%||0.81%|
一、与主营业务无关的业务收入||||
1.正常经营之外的其他业务收入。如出租固定资产、无形资产、包装物,销售材料,用材料进行非货币性资产交换,经营受托管理业务等实现的收入,以及虽计入主营业务收入,但属于上市公司正常经营之外的收入。|21,821,882.55|主要为销售材料、资产出租,不属于主营范围,需扣除|16,633,967.45|主要为销售材料、资产出租,不属于主营范围,需扣除
与主营业务无关的业务收入小计|21,821,882.55|无|16,633,967.45|无
二、不具备商业实质的收入||||
不具备商业实质的收入小计|0.00|无|0.00|无
营业收入扣除后金额|1,757,230,310.63|无|2,042,428,794.40|无
合同分类|分部1|分部2||合计
商品类型||||
其中:||||
肠胃康|184,551,872.85|||184,551,872.85
头孢制剂系列|407,462,887.39|||407,462,887.39
其他品种|500,644,010.59|||500,644,010.59
原料药及中间体|389,643,319.78|||389,643,319.78
医疗器械|104,978,509.44|||104,978,509.44
医疗服务费|169,949,710.58|||169,949,710.58
其他收入|21,821,882.55|||21,821,882.55
按经营地区分类||||
其中:||||
国内|1,676,814,686.79|||1,676,814,686.79
国外|102,237,506.39|||102,237,506.39
市场或客户类型||||
其中:||||
||||
合同类型||||
其中:||||
||||
按商品转让的时间分||||
类||||
其中:||||
||||
按合同期限分类||||
其中:||||
||||
按销售渠道分类||||
其中:||||
||||
合计|1,779,052,193.18|||1,779,052,193.18
本报告期末已签订合同、但尚未履行或尚未履行完毕的履约义务所对应的收入金额为0.00元,其中,0.00 元预计将于0.00 年度确认收入,0.00 元预计将于0.00 年度确认收入,0.00 元预计将于0.00 年度确认收入。
项目|本期发生额|上期发生额
城市维护建设税|4,971,594.32|5,545,300.62
教育费附加|3,815,556.72|4,213,265.23
房产税|7,777,993.85|6,460,690.46
土地使用税|3,402,408.87|3,286,494.51
车船使用税|13,244.55|12,923.10
印花税|1,158,285.39|1,361,533.86
其他|497,494.11|1,172,785.41
合计|21,636,577.81|22,052,993.19
项目|本期发生额|上期发生额
市场开发费|458,190,132.12|539,503,784.09
职工薪酬|32,542,229.20|31,563,522.48
广告费|11,327,148.56|683,787.15
会议费|748,597.34|1,735,354.84
差旅费|3,170,251.87|3,461,409.48
运输费|33,852.37|847,393.58
其他|16,899,728.73|50,239,790.73
合计|522,911,940.19|628,035,042.35
项目|本期发生额|上期发生额
职工薪酬|87,041,314.20|97,894,835.74
差旅费|1,505,717.58|2,862,660.77
折旧费|20,174,149.96|24,272,990.25
无形资产摊销|15,459,015.24|10,972,126.20
办公费|2,797,844.76|3,399,149.46
业务招待费|2,330,066.40|3,145,480.56
咨询费|12,259,890.79|26,189,878.19
董事会费|80,000.04|1,337,621.68
停工损失|27,660,597.13|52,780,572.49
其他|28,648,508.33|34,007,482.05
合计|197,957,104.43|256,862,797.39
项目|本期发生额|上期发生额
委托外部研发费|29,301,611.41|63,885,119.68
折旧与摊销费|5,194,264.31|21,905,114.17
研发人员薪酬|1,601,907.78|18,971,565.49
材料、燃料动力费|3,225,635.01|85,279,960.30
中间试验费|116,735.37|111,516.64
其他|9,713,653.98|6,541,160.91
合计|49,153,807.86|196,694,437.19
项目|本期发生额|上期发生额
利息支出|218,195,842.70|248,663,669.60
减:利息收入|49,435,729.19|55,727,491.20
汇兑损益|-2,110,910.92|2,186,503.10
其他|604,065.94|2,886,178.01
合计|167,253,268.53|198,008,859.51
产生其他收益的来源|本期发生额|上期发生额
政府补助|22,139,221.31|25,678,573.44
个税返还|147,779.17|22,054.23
合计|22,287,000.48|25,700,627.67
项目|本期发生额|上期发生额
权益法核算的长期股权投资收益|-59,340,738.39|-32,050,446.11
处置长期股权投资产生的投资收益|303,338,683.69|40,720,934.89
交易性金融资产在持有期间的投资收益|9,189,365.52|12,088,448.95
处置交易性金融资产取得的投资收益|-94,382.84|-523,710.89
其他权益工具投资在持有期间取得的股利收入||8,571,488.84
其他|1,893,702.05|0.00
合计|254,986,630.03|28,806,715.68
产生公允价值变动收益的来源|本期发生额|上期发生额
交易性金融资产|-57,760,523.17|-190,937,542.30
合计|-57,760,523.17|-190,937,542.30
项目|本期发生额|上期发生额
坏账损失|-103,870,295.59|-419,349,975.67
预计负债损失|-3,985,557.50|-153,831,706.41
合计|-107,855,853.09|-573,181,682.08
项目|本期发生额|上期发生额
二、存货跌价损失及合同履约成本减值损失|-518,124.41|-5,324,127.40
三、长期股权投资减值损失|-1,292,438.09|-259,944,143.23
五、固定资产减值损失|0.00|-56,547,780.00
七、在建工程减值损失|0.00|84,880.00
十一、商誉减值损失|0.00|-52,628,700.00
合计|-1,810,562.50|-374,359,870.63
资产处置收益的来源|本期发生额|上期发生额
非流动资产处置损益|19,352,800.82|3,396,192.25
合计|19,352,800.82|3,396,192.25
项目|本期发生额|上期发生额|计入当期非经常性损益的金额
接受捐赠|480,310.32|480,310.32|480,310.32
违约赔偿收入|1,360,552.67|1,196,898.59|1,360,552.67
债务核销|2,038,976.62|0.00|2,038,976.62
其他|538,112.17|1,268,749.16|538,112.17
合计|4,417,951.78|2,945,958.07|4,417,951.78
项目|本期发生额|上期发生额|计入当期非经常性损益的金额
对外捐赠|91,920.36|17,816.71|91,920.36
盘亏损失|0.00|449.34|
非流动资产毁损报废损失|668,061.19|1,223,995.81|668,061.19
滞纳金及罚款支出|879,478.56|6,318,527.76|879,478.56
其他|190,049.80|147,399.91|190,049.80
合计|1,829,509.91|7,708,189.53|1,829,509.91
项目|本期发生额|上期发生额
当期所得税费用|47,893,348.32|5,788,793.44
递延所得税费用|-109,166,746.71|35,863,292.96
合计|-61,273,398.39|41,652,086.40
项目|本期发生额
利润总额|-58,896,347.40
按法定/适用税率计算的所得税费用|-14,724,086.85
子公司适用不同税率的影响|-5,825,084.90
调整以前期间所得税的影响|-39,781,471.50
非应税收入的影响|-14,001,478.38
不可抵扣的成本、费用和损失的影响|3,756,235.73
使用前期未确认递延所得税资产的可抵扣亏损的影响|-70,660,566.97
本期未确认递延所得税资产的可抵扣暂时性差异或可抵扣亏损的影响|87,429,654.03
研发费用加计扣除|-7,466,599.54
所得税费用|-61,273,398.39
详见附注十节/七/57。
项目|本期发生额|上期发生额
收回往来款|36,472,213.42|73,174,008.59
收到银行存款利息收入|4,605,208.96|7,203,370.53
收到财政补贴资金|48,999,378.26|40,681,366.55
收到保证金|1,392,880.00|27,439,116.44
收到其他|6,263,766.95|9,758,895.20
合计|97,733,447.59|158,256,757.31
项目|本期发生额|上期发生额
支付销售费用、管理费用等|547,906,131.82|626,786,010.09
支付往来款|39,068,459.38|44,009,305.63
支付保证金|13,772,837.35|30,593,516.51
其他|16,186,738.52|19,030,669.03
合计|616,934,167.07|720,419,501.26
项目|本期发生额|上期发生额
收回定期存单款项|54,281,510.14|690,065,192.68
收回单位借款|158,272,455.78|4,991,384.95
其他|1,891,724.86|2,304,669.33
合计|214,445,690.78|697,361,246.96
项目|本期发生额|上期发生额
支付定期存单款项|21,284,156.95|70,000,000.00
其他|381,250.02|8,100,000.00
合计|21,665,406.97|78,100,000.00
项目|本期发生额|上期发生额
收到外部借款|237,500,000.00|1,801,899,068.38
融资租赁融资款|207,697,946.07|740,524,888.89
保证金|108,346,388.70|175,268,247.49
其他|10,945,890.67|19,269,356.58
合计|564,490,225.44|2,736,961,561.34
项目|本期发生额|上期发生额
偿还融资租赁借款本金|237,500,000.00|355,943,148.49
归还外部借款|1,264,253,191.02|1,690,903,464.14
支付保证金|84,535,301.48|109,745,000.00
其他|0.00|15,099,800.41
合计|1,586,288,492.50|2,171,691,413.04
补充资料|本期金额|上期金额
1.将净利润调节为经营活动现金流量||
净利润|2,377,050.99|-1,597,625,582.17
加:资产减值准备|1,810,562.50|374,359,870.63
信用减值损失|107,855,853.09|573,181,682.08
固定资产折旧、油气资产折耗、生产性生物资产折旧|131,392,635.42|151,024,719.20
使用权资产折旧|474,489.81|0.00
无形资产摊销|21,380,343.16|25,252,322.47
长期待摊费用摊销|7,793,621.98|11,266,013.28
处置固定资产、无形资产和其他长期资产的损失(收益以“-”号填列)|-19,352,800.82|-3,396,192.25
固定资产报废损失(收益以“-”号填列)|668,061.19|1,223,995.81
公允价值变动损失(收益以“-”号填列)|57,760,523.17|190,937,542.30
财务费用(收益以“-”号填列)|218,195,842.70|248,663,669.60
投资损失(收益以“-”号填列)|-254,986,630.03|-28,806,715.68
递延所得税资产减少(增加以“-”号填列)|30,279,244.48|60,722,594.48
递延所得税负债增加(减少以“-”号填列)|-98,389,220.36|-24,797,544.97
存货的减少(增加以“-”号填列)|-6,965,235.01|40,862,758.86
经营性应收项目的减少(增加以“-”号填列)|216,008,867.74|-139,805,994.26
经营性应付项目的增加(减少以“-”号填列)|-274,132,547.91|225,160,301.74
其他||
经营活动产生的现金流量净额|142,170,662.10|108,223,441.12
2.不涉及现金收支的重大投资和筹资活动||
债务转为资本||
一年内到期的可转换公司债券||
融资租入固定资产||
3.现金及现金等价物净变动情况:||
现金的期末余额|324,564,474.36|548,508,902.93
减:现金的期初余额|548,508,902.93|382,540,334.91
加:现金等价物的期末余额||
减:现金等价物的期初余额||
现金及现金等价物净增加额|-223,944,428.57|165,968,568.02
|金额
本期处置子公司于本期收到的现金或现金等价物|238,220,000.00
其中:|
上海力声特医学科技有限公司|238,220,000.00
减:丧失控制权日子公司持有的现金及现金等价物|19,111,367.07
其中:|
上海力声特医学科技有限公司|19,111,367.07
其中:|
处置子公司收到的现金净额|219,108,632.93
项目|期末余额|期初余额
一、现金|324,564,474.36|548,508,902.93
其中:库存现金|0.00|75,800.00
可随时用于支付的银行存款|324,564,474.36|548,433,102.93
三、期末现金及现金等价物余额|324,564,474.36|548,508,902.93
项目|期末账面价值|受限原因
货币资金|69,966,145.49|保证金、定期存款
固定资产|852,239,272.23|抵押
无形资产|178,903,703.70|抵押
投资性房地产|16,501,947.83|抵押
在建工程|309,569,460.20|抵押
其他权益工具|14,290,000.00|质押
长期股权投资|337,448,043.42|质押
合计|1,778,918,572.87|
项目|期末外币余额|折算汇率|期末折算人民币余额
货币资金|||
其中:美元|2,057,317.71|6.9646|14,328,394.92
欧元|||
港币|295.76|0.8933|264.20
|||
应收账款|||
其中:美元|1,017,829.80|6.9646|7,088,777.43
欧元|||
港币|||
其他应收款|||
其中:美元|100,000.00|6.9646|696,460.00
长期借款|||
其中:美元|||
重要的境外经营实体|境外主要经营地|记账本位币|选择依据
海药国际集团有限公司|香港|港币|经营当地流通货币
种类|金额|列报项目|计入当期损益的金额
计入递延收益的政府补助|31,330,000.00|详见附注51|6,228,571.62
计入其他收益的政府补助|15,910,649.69|详见附注67|15,910,649.69
合计|47,240,649.69||22,139,221.31